NasdaqGM:KEQU

Stock Analysis Report

Executive Summary

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products.

Snowflake

Fundamentals

Adequate balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Kewaunee Scientific's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.6%

KEQU

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-44.7%

KEQU

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: KEQU underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: KEQU underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

KEQUIndustryMarket
7 Day-1.6%2.0%1.8%
30 Day-3.1%-1.8%-0.7%
90 Day-16.0%-0.5%0.06%
1 Year-42.6%-44.7%14.2%13.3%9.7%7.3%
3 Year-23.9%-30.1%70.5%65.3%46.3%36.9%
5 Year0.7%-12.7%127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Kewaunee Scientific's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kewaunee Scientific undervalued compared to its fair value and its price relative to the market?

83.28x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: KEQU ($15.5) is trading above our estimate of fair value ($13.61)

Significantly Undervalued: KEQU is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: KEQU is poor value based on its PE Ratio (83.3x) compared to the Medical Equipment industry average (41.8x).

PE vs Market: KEQU is poor value based on its PE Ratio (83.3x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate KEQU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KEQU is good value based on its PB Ratio (0.9x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Kewaunee Scientific forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

17.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KEQU's forecast earnings growth (17.6% per year) is above the savings rate (2.7%).

Earnings vs Market: KEQU's earnings (17.6% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: KEQU's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if KEQU's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KEQU's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if KEQU's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Kewaunee Scientific performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: KEQU's earnings have grown by 0.2% per year over the past 5 years.

Accelerating Growth: KEQU's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: KEQU had negative earnings growth (-90.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (28.2%).


Return on Equity

High ROE: KEQU's Return on Equity (1.4%) is considered low.


Return on Assets

ROA vs Industry: KEQU's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: KEQU's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Kewaunee Scientific's financial position?


Financial Position Analysis

Short Term Liabilities: KEQU's short term assets ($69.0M) exceeds its short term liabilities ($38.0M)

Long Term Liabilities: KEQU's short term assets (69.0M) exceeds its long term liabilities (12.6M)


Debt to Equity History and Analysis

Debt Level: KEQU's debt to equity ratio (29.7%) is considered satisfactory

Reducing Debt: KEQU's debt to equity ratio has increased from 27.4% to 29.7% over the past 5 years.

Debt Coverage: KEQU's debt is well covered by operating cash flow (34.5%).

Interest Coverage: KEQU's interest payments on its debt are not well covered by EBIT (2.9x coverage).


Balance Sheet

Inventory Level: KEQU has a high level of physical assets or inventory.

Debt Coverage by Assets: KEQU's debt is covered by short term assets (assets are 4.841900x debt).


Next Steps

Dividend

What is Kewaunee Scientific's current dividend yield, its reliability and sustainability?

4.90%

Current Dividend Yield


Dividend Yield vs Market

company4.9%marketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: KEQU's dividend (4.9%) is higher than the bottom 25% of dividend payers in the US market (1.45%).

High Dividend: KEQU's dividend (4.9%) is in the top 25% of dividend payers in the US market (3.72%)

Stable Dividend: KEQU's dividends per share have been stable in the past 10 years.

Growing Dividend: KEQU's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (408.3%), KEQU's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Kewaunee Scientific's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average management tenure


CEO

Thomas Hull (43yo)

0.6yrs

Tenure

US$403,701

Compensation

Mr. Thomas D. Hull, III, has been President and Chief Executive Officer at Kewaunee Scientific Corporation since March 11, 2019 and served as its Chief Financial Officer since November 1, 2015 until April  ...


CEO Compensation Analysis

Compensation vs. Market: Thomas has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.5yrs

Average Tenure

50yo

Average Age

Experienced Management: KEQU's management team is considered experienced (3.5 years average tenure).


Board Age and Tenure

5.4yrs

Average Tenure

63yo

Average Age

Experienced Board: KEQU's board of directors are considered experienced (5.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$4,96718 Mar 19
Ryan Noble
EntityIndividual
Shares232
Max PriceUS$21.41

Ownership Breakdown


Management Team

  • Kurt Rindoks (61yo)

    Vice President of Product Development & International Sourcing

    • Tenure: 23.1yrs
    • Compensation: US$223.18k
  • Keith Smith (50yo)

    Director of Metal Plant Operations and Facilities

    • Tenure: 3.5yrs
    • Compensation: US$260.43k
  • Elizabeth Phillips (42yo)

    Vice President of Human Resources

    • Tenure: 10.3yrs
  • Sathya Sathyamurthy (50yo)

    MD of International Operations & VP of Kewaunee Scientific Corporation Singapore Pte. Ltd.

    • Tenure: 0yrs
  • Thomas Hull (43yo)

    President

    • Tenure: 0.6yrs
    • Compensation: US$403.70k
  • Mike Rok (53yo)

    Vice President of Manufacturing Operations

    • Tenure: 3.4yrs
    • Compensation: US$312.29k
  • Don Gardner (40yo)

    VP of Finance

    • Tenure: 0.5yrs

Board Members

  • Keith Gehl (60yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: US$91.99k
  • David Rhind (56yo)

    Chairman

    • Tenure: 0.7yrs
    • Compensation: US$90.13k
  • Margaret Pyle (67yo)

    Director

    • Tenure: 24.7yrs
    • Compensation: US$83.25k
  • Don Shaw (68yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$87.00k
  • John Russell (66yo)

    Director

    • Tenure: 8.4yrs
    • Compensation: US$89.50k
  • Thomas Hull (43yo)

    President

    • Tenure: 0.6yrs
    • Compensation: US$403.70k

Company Information

Kewaunee Scientific Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kewaunee Scientific Corporation
  • Ticker: KEQU
  • Exchange: NasdaqGM
  • Founded: 1906
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$42.627m
  • Shares outstanding: 2.75m
  • Website: https://www.kewaunee.com

Number of Employees


Location

  • Kewaunee Scientific Corporation
  • 2700 West Front Street
  • Statesville
  • North Carolina
  • 28677
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KEQUNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1980

Biography

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The company operates in two segments, Domestic and International. Its products  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:39
End of Day Share Price2019/10/17 00:00
Earnings2019/07/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.